Lore Lannoo

Lore Lannoo

Auto-generated profile, based on publicly available information

Lore Lannoo

Department of Gynecology and Obstetrics, University Hospitals Leuven, Leuven, BELGIUM

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2009 in International Journal of Gynecological Cancer
Verified
Journal Article
Open access
PDF file
FAFrédéric Amant
Frédéric Amant
KCKristel Van Calsteren
Kristel Van Calsteren
MHMichael J. Halaska
Michael J. Halaska
JBJos Beijnen
Jos Beijnen
LLLieven Lagae
Lieven Lagae
ABAndreas Du Bois
Andreas Du Bois
Background: Gynecologic cancer during pregnancy is a special challenge because cancer or its treatment may affect not only the pregnant women in general but directly involve the reproductive tract and fetus. Currently, there are no guidelines on how to deal with this special coincidence. Methods: An international consensus meeting on staging and treatment of gynecological malignancies during pregnancy was organised including a systematic literature search, and interpretation followed by a physical meeting of all participants with intensive discussion. In the absence of large trials and randomized studies, recommendations were based on available literature data and personal experience thus representing a low but best achievable level of evidence. Findings: Randomized trials and prospective studies on cancer treatment during pregnancy are lacking. Gynecological cancer during pregnancy is a demanding problem, and multidisciplinary expertise should be available. Counseling both parents on the maternal prognosis and fetal risk is needed. When there is a firm desire to continue the pregnancy, gynecological cancer can be treated in selected cases. The staging and treatment should follow the standard approach as much as possible. Guidelines for safe pelvic surgery during pregnancy are presented. Mainly in cervical and ovarian cancer, chemotherapy and an alternative surgical approach need to be considered. Administration of chemotherapy during the second or third trimester may probably not increase the incidence of congenital malformations. Until now, the long-term outcome of children in utero exposed to oncological treatment modalities is poorly documented, but preterm birth on its own is associated with cognitive impairment. Delivery should be postponed preferably until after a gestational age of 35 weeks. Interpretation: Further research including international registries for gynecologic cancer in pregnancy is urgently needed. The gathering of both available literature and personal experience allowed only suggesting models for treatment of gynecologic cancer in pregnancy.

12 March 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
KSKate E. Stanley
Kate E. Stanley
TJTatjana Jatsenko
Tatjana Jatsenko
STStefania Tuveri
Stefania Tuveri
DSDhanya Sudhakaran
Dhanya Sudhakaran
LLLore Lannoo
Lore Lannoo
JVJoris Vermeesch
Joris Vermeesch
Circulating cell-free DNA (cfDNA) fragments have characteristics that are specific to the cell types that release them. Current methods for cfDNA deconvolution typically use disease tailored marker selection in a limited number of bulk tissues or cell lines. Here, we utilize single cell transcriptome data as a comprehensive cellular reference set for disease-agnostic cfDNA cell-of-origin analysis. We correlate cfDNA-inferred nucleosome spacing with gene expression to rank the relative contribution of over 490 cell types to plasma cfDNA. In 744 healthy individuals and patients, we uncover cell type signatures in support of emerging disease paradigms in oncology and prenatal care. We train predictive models that can differentiate patients with colorectal cancer (84.7%), early-stage breast cancer (90.1%), multiple myeloma (AUC 95.0%), and preeclampsia (88.3%) from matched controls. Importantly, our approach performs well in ultra-low coverage cfDNA datasets and can be readily transferred to diverse clinical settings for the expansion of liquid biopsy.

1 May 2021 in eClinicalMedicine
Verified
Journal Article
Open access
LLLiesbeth Lenaerts
Liesbeth Lenaerts
NBNathalie Brison
Nathalie Brison
CMCharlotte Maggen
Charlotte Maggen
LVLeen Vancoillie
Leen Vancoillie
HCHuiwen Che
Huiwen Che
FAFrédéric Amant
Frédéric Amant
Implausible false positive results in non-invasive prenatal testing (NIPT) have been occasionally associated with the detection of occult maternal malignancies. Hence, there is a need for approaches allowing accurate prediction of whether the NIPT result is pointing to an underlying malignancy, as well as for organized programs ensuring efficient downstream clinical management of these cases. Using a data set of 88,294 NIPT performed at University Hospital Leuven (Belgium) between November 2013 and March 2020, we retrospectively evaluated the positive predictive value (PPV) of our NIPT approach for cancer detection. In this approach, whole-genome cell-free DNA (cfDNA) data from NIPT were scrutinized for the presence of (sub)chromosomal copy number alterations (CNAs) predictive for a malignancy, using an unbiased NIPT analysis pipeline coined GIPSeq. For suspected cases, the presence of a maternal cancer was evaluated via subsequent multidisciplinary clinical follow-up examinations. The cancer-specificity of the identified CNAs in cfDNA was assessed through genetic analyses of a tumor biopsy. Fifteen women without a cancer history were identified with a GIPSeq result suggestive of a malignant process. Their cfDNA profiles showed either genome-wide aberrations or a single trisomy 8. Upon clinical examinations, a solid or hematological cancer was identified in 4 and 7 cases, respectively. Three women were identified as having a clonal mosaicism. For one case no underlying condition was found. These numbers add to a PPV of 73%. Based on this experience, we presented a multidisciplinary care path for efficient clinical management of these cases. The presented approach for analysing NIPT results has a high PPV, yet unknown sensitivity, for detecting asymptomatic malignancies upon routine NIPT. Given the complexity of diagnosing a pregnant woman with cancer, clinical follow-up should occur in a well-designed multidisciplinary setting, such as via the care model that we presented here. This work was supported by Research Foundation Flanders and KU Leuven funding.

11 December 2009 in Gynecologic and Obstetric Investigation
Verified
Journal Article
Closed access
CHCaroline Van Holsbeke
Caroline Van Holsbeke
ADAnneleen Daemen
Anneleen Daemen
JYJoseph Yazbek
Joseph Yazbek
THTom K. Holland
Tom K. Holland
TBTom Bourne
Tom Bourne
DTDirk Timmerman
Dirk Timmerman
Aim: To determine how accurately and confidently examiners with different levels of ultrasound experience can classify adnexal masses as benign or malignant and suggest a specific histological diagnosis when evaluating ultrasound images using pattern recognition. Methods: Ultrasound images of selected adnexal masses were evaluated by 3 expert sonologists, 2 senior and 4 junior trainees. They were instructed to classify the masses using pattern recognition as benign or malignant, to state the level of confidence with which this classification was made and to suggest a specific histological diagnosis. Sensitivity, specificity, accuracy and positive and negative likelihood ratios (LR+ and LR–) with regard to malignancy were calculated. The area under the receiver operating characteristic curve (AUC) of pattern recognition was calculated by using six levels of diagnostic confidence. Results: 166 masses were examined, of which 42% were malignant. Sensitivity with regard to malignancy ranged from 80 to 86% for the experts, was 70 and 84% for the 2 senior trainees and ranged from 70 to 86% for the junior trainees. The specificity of the experts ranged from 79 to 91%, was 77 and 89% for the senior trainees and ranged from 59 to 83% for the junior trainees. The experts were uncertain about their diagnosis in 4–13% of the cases, the senior trainees in 15–20% and the junior trainees in 67–100% of the cases. The AUCs ranged from 0.861 to 0.922 for the experts, were 0.842 and 0.855 for the senior trainees, and ranged from 0.726 to 0.795 for the junior trainees. The experts suggested a correct specific histological diagnosis in 69–77% of the cases. All 6 trainees did so significantly less often (22–42% of the cases). Conclusion: Expert sonologists can accurately classify adnexal masses as benign or malignant and can successfully predict the specific histological diagnosis in many cases. Whilst less experienced operators perform reasonably well when predicting the benign or malignant nature of the mass, they do so with a very low level of diagnostic confidence and are unable to state the likely histology of a mass in most cases.

27 July 2022 in European Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
LLLore Lannoo
Lore Lannoo
KSKhaila van Straaten
Khaila van Straaten
JBJeroen Breckpot
Jeroen Breckpot
NBNathalie Brison
Nathalie Brison
LCLuc De Catte
Luc De Catte
KDKoenraad Devriendt
Koenraad Devriendt

8 September 2009 in Ultrasound in Obstetrics & Gynecology
Verified
Journal Article
Closed access
PDF file
CHC. Van Holsbeke
C. Van Holsbeke
ADA. Daemen
A. Daemen
JYJ. Yazbek
J. Yazbek
THT. K. Holland
T. K. Holland
TBT. Bourne
T. Bourne
DTD. Timmerman
D. Timmerman